Get the Stockscreener App
2.88
3.68%
-0.11
After Hours:
2.95
0.07
+2.43%
Fortress Biotech Inc stock is traded at $2.88, with a volume of 734.16K.
It is down -3.68% in the last 24 hours and down -18.18% over the past month.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
See More
Previous Close:
$2.99
Open:
$2.9
24h Volume:
734.16K
Relative Volume:
0.79
Market Cap:
$89.39M
Revenue:
$62.30M
Net Income/Loss:
$-53.83M
P/E Ratio:
-10.76
EPS:
-0.2677
Net Cash Flow:
$-30.14M
1W Performance:
-8.28%
1M Performance:
-18.18%
6M Performance:
-26.34%
1Y Performance:
+71.43%
1-Day Range:
$2.75
$3.01
1-Week Range:
$2.75
$3.14
52-Week Range:
$1.325
$4.53
Fortress Biotech Inc Stock (FBIO) Company Profile
Name
Fortress Biotech Inc
Sector
Industry
Phone
781-652-4500
Address
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare FBIO vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
2.88 | 92.80M | 62.30M | -53.83M | -30.14M | -0.2677 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-15-24 | Resumed | ROTH MKM | Buy |
| Aug-04-22 | Initiated | Ladenburg Thalmann | Buy |
| Oct-02-20 | Initiated | The Benchmark Company | Buy |
| Dec-18-19 | Initiated | B. Riley FBR | Buy |
| Feb-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
| Mar-22-17 | Initiated | JMP Securities | Mkt Outperform |
| Oct-03-16 | Initiated | ROTH Capital | Buy |
View All
Fortress Biotech Inc Stock (FBIO) Latest News
Fortress Biotech Inc Stock: Journey Medical's Strong 2025 Results Highlight Growth Potential in Derm - AD HOC NEWS
Portfolio Recap: How does Fortress Biotech Inc score in quality rankingsOptions Play & Safe Entry Point Alerts - baoquankhu1.vn
Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights - GlobeNewswire
Portfolio Shifts: Can Fortress Biotech Inc deliver alphaQuarterly Earnings Summary & Smart Money Movement Alerts - baoquankhu1.vn
Fortress Biotech (FBIO) Projected to Post Quarterly Earnings on Monday - MarketBeat
Fortress Biotech to Receive $205M as Cyprium Agrees Sale of Rare Pediatric Disease Priority Review Voucher - MSN
Buyback Watch: How liquid is Fortress Biotech Inc stock2026 Recap & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Fortress Biotech (FBIO) CEO Lindsay Rosenwald reports 20.7% ownership in 13D/A - Stock Titan
Fortress Biotech (FBIO) Executive Vice Chairman granted 475,424 restricted shares - Stock Titan
FORTRESS BIOTECH INC 9.375% Cumulative Redeemable Preferred Stock Series A USD25.00 (FBIOP.US) will release its earnings report after the market closes on March 25. - 富途牛牛
Mustang Bio, Inc. 2025 Annual Report: Clinical-Stage Biopharmaceutical Pipeline, Risks, and Regulatory Overview - Minichart
Mustang Bio (NASDAQ: MBIO) details GBM pipeline, Orphan status and cash - Stock Titan
Fortress Biotech (NASDAQ:FBIO) Cut to "Hold" at Zacks Research - MarketBeat
Fortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Macro Review: How do insiders feel about Fortress Biotech IncMarket Movers & Verified Momentum Stock Alerts - baoquankhu1.vn
Understanding Momentum Shifts in (FBIOP) - Stock Traders Daily
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 - The Globe and Mail
Quarterly Earnings: Should value investors consider Fortress Biotech Inc2026 Growth vs Value & Consistent Profit Trade Alerts - baoquankhu1.vn
Fortress Biotech Inc Stock (ISIN: US32015L1035) Faces Short Interest Pressure Amid Biotech Sector Vo - AD HOC NEWS
Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Swing Trade: How do insiders feel about Fortress Biotech IncCEO Change & Daily Technical Forecast Reports - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (FBIOP) Movement - Stock Traders Daily
Aug Sectors: How do insiders feel about Fortress Biotech IncMarket Performance Recap & Technical Entry and Exit Tips - baoquankhu1.vn
Aug Opening: What are the risks of holding Fortress Biotech IncJuly 2025 PreEarnings & Risk Controlled Swing Alerts - baoquankhu1.vn
Why Is Fortress Biotech Stock Falling Today? - Stocktwits
FBIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Weekly Trades: Will Fortress Biotech Inc outperform during market ralliesTreasury Yields & Technical Pattern Recognition Alerts - baoquankhu1.vn
Gap Down: Will Fortress Biotech Inc outperform during market ralliesNew Guidance & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Fortress Biotech (NASDAQ:FBIO) Stock Passes Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Fortress Biotech (NASDAQ:FBIO) Stock Passes Above Two Hundred Day Moving Average – Here’s Why - Defense World
Discipline and Rules-Based Execution in FBIOP Response - Stock Traders Daily
Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M - Yahoo Finance
Fortress Biotech’s (FBIO) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
FBIO: HC Wainwright & Co. Reiterates Buy Rating on Fortress Biot - GuruFocus
FBIO Eyes Future Growth Amid Financial Optimism - StocksToTrade
FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy - Stocktwits
FBIO: HC Wainwright & Co. Reiterates Buy Rating on Fortress Biotech | FBIO Stock News - GuruFocus
Fortress Biotech Inc. Shares Soar After Promising New Developments - timothysykes.com
Fortress Biotech's (FBIO) Buy Rating Reiterated at HC Wainwright - MarketBeat
Fortress Biotech: PRV Windfall and De-Risked Zycubo Economics Support Buy Rating and $17 Target - TipRanks
Fortress Biotech (FBIO) Sells Priority Review Voucher for $205 M - GuruFocus
Fortress Biotech Inc. Faces Stock Volatility Amid Strategic Adjustments - StocksToTrade
Fortress Biotech, Inc. and Cyprium Therapeutics Enter Asset Purchase Agreement for $205 Million Rare Pediatric Disease Priority Review Voucher - Quiver Quantitative
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics - GlobeNewswire
UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - Yahoo Finance
Strategic Acquisition Sends Fortress Biotech Stocks Soaring - timothysykes.com
Fortress Biotech Subsidiary Agrees to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - marketscreener.com
Cyprium Voucher Sale Bolsters Fortress Biotech Liquidity - TipRanks
Fortress Biotech Monetizes PRV for $205 Million; Amends Oaktree Credit Facility - TradingView
After Menkes drug approval, Fortress moves to cash in $205M voucher - Stock Titan
Avenue Therapeutics Enters into Exclusive Worldwide License - GlobeNewswire
Fortress Biotech Inc Stock (FBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):